HC Wainwright & Co. Reiterates Neutral on Kyverna Therapeutics, Maintains $7 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated a Neutral rating for Kyverna Therapeutics (NASDAQ:KYTX) and maintained a $7 price target.
September 19, 2024 | 10:55 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
HC Wainwright & Co. has reiterated a Neutral rating for Kyverna Therapeutics and maintained a $7 price target, indicating no expected short-term price movement.
The reiteration of a Neutral rating and maintenance of the $7 price target suggests that the analyst does not foresee significant short-term changes in the stock's price. This indicates stability rather than a bullish or bearish outlook.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100